A Phase 3, Multicenter, Open Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Grants and Contracts Details

StatusFinished
Effective start/end date10/10/1810/29/24

Funding

  • Celgene International II Sarl: $67,406.00